Login to Your Account

Prexton gets $10M series A funding for mGluR4 program in Parkinson's

By Cormac Sheridan
Staff Writer

Tuesday, February 24, 2015
DUBLIN – Prexton Therapeutics SA, an early stage CNS drug developer spun out of the Merck Serono arm of Merck KGaA, raised €8.7 million (US$10 million) to move a metabotropic glutamate receptor 4 (mGluR4) agonist development program into clinical trials in Parkinson's disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription